<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506298</url>
  </required_header>
  <id_info>
    <org_study_id>CRx-401-001</org_study_id>
    <nct_id>NCT00506298</nct_id>
  </id_info>
  <brief_title>Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes</brief_title>
  <official_title>A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zalicus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zalicus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking&#xD;
      metformin to treat their diabetes. In addition, this initial trial will evaluate insulin&#xD;
      resistance (HOMA-IR index), HgbA1c levels, glycated protein, LDL, HDL, triglycerides, and&#xD;
      total cholesterol, as well as the safety of CRx-401.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRx-401 (bezafibrate + diflunisal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bezafibrate + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bezafibrate + diflunisal</intervention_name>
    <description>bezafibrate + diflunisal</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bezafibrate + placebo</intervention_name>
    <description>bezafibrate + placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must voluntarily give written informed consent&#xD;
&#xD;
          -  Must be between 18-75 years of age&#xD;
&#xD;
          -  Must have Type 2 diabetes for ≥ 6 months&#xD;
&#xD;
          -  HgbA1C between 7.0% and 9.5%&#xD;
&#xD;
          -  FPG &gt; 6.7 mmol/L (120 mg/dL)&#xD;
&#xD;
          -  BMI: Lower limit of 27 kg/m2 and an upper Limit of 45 kg/m2&#xD;
&#xD;
          -  Treatment with a stable dosage for ≥ 8 weeks of either Glucophage metformin) ≥ 1000&#xD;
             and ≤ 2500 mg/day OR Glucophage XR ≤ 2000 mg/day&#xD;
&#xD;
          -  eGFR ≥ 70 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant atherosclerotic disorder including myocardial&#xD;
             infarction (within 6 months of screening), angina, stroke, peripheral vascular disease&#xD;
             or congestive heart failure&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction related to fibrates or NSAIDs&#xD;
             including photo-allergic or phototoxic reactions to fibrates&#xD;
&#xD;
          -  Subjects in whom acute asthmatic attacks, urticaria, or rhinitis are precipitated by&#xD;
             aspirin or other NSAIDs&#xD;
&#xD;
          -  History of clinically significant (as determined by the investigator cardiac,&#xD;
             hematologic, hepatobiliary, peptic ulcer, renal, immunologic, metabolic, urologic,&#xD;
             pulmonary, endocrinologic, neurologic, dermatologic, psychiatric, and/or other major&#xD;
             disease&#xD;
&#xD;
          -  Type 1 Diabetes&#xD;
&#xD;
          -  Evidence of Cushing's syndrome, untreated hypothyroidism or other disorders that may&#xD;
             lead to secondary weight gain, insulin resistance, or Type 2 diabetes&#xD;
&#xD;
          -  Proliferative diabetic retinopathy or significant neuropathic symptoms that also limit&#xD;
             activities of daily living&#xD;
&#xD;
          -  History of malignancy (except for treated or excised basal cell carcinoma)&#xD;
&#xD;
          -  Surgery within the 90 days prior to screening except for minor dental or cosmetic&#xD;
             procedures&#xD;
&#xD;
          -  History of drug or alcohol abuse (as defined by the Investigator)&#xD;
&#xD;
          -  History of opportunistic infection&#xD;
&#xD;
          -  Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,&#xD;
             septicemia) within 3 months prior to screening&#xD;
&#xD;
          -  Fever or symptomatic viral or bacterial infection within 2 weeks prior to screening&#xD;
&#xD;
          -  Positive for HCV antibody&#xD;
&#xD;
          -  Positive for HBsAg&#xD;
&#xD;
          -  Known positive for HIV antibody&#xD;
&#xD;
          -  Pharmacologic treatment with statins, unless dosage has been stable ≥ three months and&#xD;
             is unlikely to change over the course of the study.&#xD;
&#xD;
          -  Treatment with any concomitant medication that has not been at a stable dose for at&#xD;
             least 28 days prior to screening.&#xD;
&#xD;
          -  Currently taking or planning to take during the trial:&#xD;
&#xD;
        Sulphonylureas, Injected hypoglycemic (exanatide or insulin), Weight loss medications,&#xD;
        Thiazolidenediones, Glucocorticoids (inhaled glucocorticoids are permitted), Digoxin,&#xD;
        Anticoagulants, Phenytoin, Loratadine, Erythromycin, MAO-inhibitors, NSAIDs (ASA ≤ 81 mg/d&#xD;
        is permitted), COX-2 Inhibitors, Cholestryramine or fibrates, DPP-IV inhibitors, Any herbal&#xD;
        medications unless reviewed with study doctor&#xD;
&#xD;
          -  Alanine aminotransferase ALT) or aspartate aminotransferase (AST laboratory values&#xD;
             that exceed &gt; 2.0 x upper limit of normal (ULN)&#xD;
&#xD;
          -  White blood cell (WBC) count &lt; 4.0 x 109 /L or &gt;14.0 X 109 /L&#xD;
&#xD;
          -  Hemoglobin &lt; 105 g/L in females and &lt; 110 g/L in males (&lt; 10.5 g/dL in females and &lt;&#xD;
             11.0 g/dL in males)&#xD;
&#xD;
          -  Participation in another clinical trial and/or treatment received with any&#xD;
             investigational agent within 30 days before the initial dose of study medication&#xD;
&#xD;
          -  Female subject who is pregnant or lactating or of child bearing potential and not&#xD;
             using acceptable methods of contraception (birth control pills, barriers or&#xD;
             abstinence)&#xD;
&#xD;
          -  Unwilling or unable to comply with the requirements of this protocol, including the&#xD;
             presence of any condition (physical, mental, or social) that is likely to affect the&#xD;
             subject's return for follow-up visits on schedule&#xD;
&#xD;
          -  Other unspecified reasons that, in the opinion of the Investigator or sponsor make the&#xD;
             subject unsuitable for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Zmijowskyj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicor Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holyroad</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aylmer</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Collingwood</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>May 12, 2009</last_update_submitted>
  <last_update_submitted_qc>May 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>CombinatoRx</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>CRx-401</keyword>
  <keyword>Bezafibrate</keyword>
  <keyword>Diflunisal</keyword>
  <keyword>Metformin</keyword>
  <keyword>plasma glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diflunisal</mesh_term>
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

